The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the treatment algorithm with the use of Keytruda (Merck & Co.) for metastatic gastric and GEJ adenocarcinoma tumors expressing PD-L1 and Herceptin (Roche/Genentech) for HER2-positive metastatic gastric or GEJ adenocarcinoma, therapeutic options for a large proportion of metastatic patients remain severely limited. Cyramza (Eli Lilly), with or without paclitaxel, is frequently prescribed for second- and subsequent-line treatment of metastatic gastric and GEJ adenocarcinoma. Cytotoxic monotherapies and doublet or triplet chemotherapy regimens remain a mainstay of treatment. The substantial unmet medical need for therapeutic management of metastatic gastric and GEJ adenocarcinoma with efficacious and well-tolerated novel therapies presents an attractive opportunity for drug developers.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
  • How do current therapies perform on key treatment drivers and goals for metastatic gastric and GEJ adenocarcinoma?
  • What are the prevailing areas of unmet need and opportunity in metastatic gastric and GEJ adenocarcinoma?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2018.

Key companies: Roche/Genentech, Eli Lilly, Merck & Co.

Key drugs: Herceptin, Cyramza, Keytruda.

Table of contents

  • Gastroesophageal Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU)

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, M.Pharm., Ph.D., is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her Ph.D. research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at G.J. University of Science & Technology, Hisar, India.


Related Reports

Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma&mdas...

View Details

Gastroesophageal Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU) Previously Treated Metastatic Gastric And Gastroesophageal Junction (GEJ) Adenocarcinoma

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastati...

View Details

Gastroesophageal Cancer - Geographic Focus - China - Gastric Cancer - China In-Depth - China

MARKET OUTLOOKChina has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Onl...

View Details

Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2019

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroes...

View Details